Mycoplasma pneumoniae with para-infectious cerebral complications
Related Experiment Video
Updated: Jan 23, 2026

Antigen-Capture Enzyme-Linked Immunosorbent Assay for Specific Detection of Mycoplasma pneumoniae
Published on: February 24, 2023
Johanna M Birrell1, Emily Woolnough1, Emma Spencer1
1Royal Darwin Hospital, 105 Rocklands Drive, Tiwi, NT, 0810, Australia.
Abstract:
Mycoplasma pneumoniae infection most commonly manifests as a mild respiratory illness and headache. Pneumonia occurs in approximately 10% of patients with respiratory symptoms. M. pneumoniae infection can also cause neurological and other extrapulmonary complications. In this case report we describe a 33-year-old Caucasian man presenting with headache and raised intracranial pressure, found to be a para-infectious complication of M. pneumoniae infection. Nasopharyngeal PCR was highly useful in facilitating early diagnosis, as IgM antibodies were negative during the early stages of illness. Azithromycin is the preferred agent for M. pneumoniae treatment. The addition of M. pneumoniae PCR to hospitals' rapid respiratory viral PCR panels could promote early directed therapy and antimicrobial stewardship.
Insights
Mycoplasma pneumoniae infection can cause serious neurological issues like raised intracranial pressure. Early diagnosis using nasopharyngeal PCR is crucial for timely treatment with azithromycin.
Area of Science:
- Infectious Diseases
- Neurology
- Microbiology
Background:
- Mycoplasma pneumoniae commonly causes mild respiratory illness.
- Extrapulmonary complications, including neurological manifestations, can occur.
- Raised intracranial pressure is a rare but serious complication.
Observation:
- A 33-year-old man presented with headache and elevated intracranial pressure.
- The patient's symptoms were a para-infectious complication of Mycoplasma pneumoniae infection.
- Nasopharyngeal PCR confirmed Mycoplasma pneumoniae, while IgM antibodies were initially negative.
Findings:
- Nasopharyngeal PCR facilitated early diagnosis of Mycoplasma pneumoniae infection.
- Azithromycin is the recommended treatment for Mycoplasma pneumoniae.
- Early detection of Mycoplasma pneumoniae is essential for managing neurological complications.
Implications:
- Integrating Mycoplasma pneumoniae PCR into respiratory viral panels can improve patient outcomes.
- Early directed therapy enhances antimicrobial stewardship.
- Recognizing neurological complications of Mycoplasma pneumoniae is vital for clinicians.
Related Concept Videos
Pneumonia III: Complications and Assessment
Directing Effect of Substituents: ortho–para-Directing Groups
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia II: Pathophysiology
ortho–para-Directing Deactivators: Halogens
Hemodialysis II: Procedure and Complications

